Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of melatonin to preparation of medicine for treating autoimmune prostatitis and medicine for treating autoimmune prostatitis

An autoimmune, prostatitis technology, applied in the field of pharmaceutical applications, can solve problems such as unsatisfactory treatment methods for patients and doctors, and unclear etiology

Pending Publication Date: 2021-06-04
THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the etiology of CP / CPPS is still unclear, current treatment options for CP / CPPS are not satisfactory to patients and physicians
However, there is no research on whether melatonin plays a protective role against CP / CPPS by activating Sirt1

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of melatonin to preparation of medicine for treating autoimmune prostatitis and medicine for treating autoimmune prostatitis
  • Application of melatonin to preparation of medicine for treating autoimmune prostatitis and medicine for treating autoimmune prostatitis
  • Application of melatonin to preparation of medicine for treating autoimmune prostatitis and medicine for treating autoimmune prostatitis

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0022] In the present invention, the source of the melatonin is not particularly limited, and commercially available products well known in the art will suffice. In the present invention, the melatonin is used in the form of injection, and the preparation method of the injection of melatonin comprises: dissolving melatonin in dimethyl sulfoxide, mixing the resulting solution with normal saline, Get melatonin injections.

[0023] In the present invention, the mass concentration of the solution obtained by dissolving melatonin in dimethyl sulfoxide is preferably 0.1-0.2%; Salt water will do. The present invention has no special limitation on the mixing process of the obtained solution and physiological saline, as long as the materials can be mixed uniformly according to the well-known process in the art.

[0024] In the present invention, the concentration of melatonin in the melatonin injection is preferably 3-8 mg / mL, more preferably 4-6 mg / mL. In the present invention, the...

Embodiment 1

[0050] (1) The mouse model of autoimmune prostatitis was established by subcutaneously injecting the mixture of prostate antigen and complete Freund's adjuvant (volume ratio 1:1) into non-obese diabetic mice (NOD) on day 0 and day 28 ( EAP);

[0051] (2) Preparation of melatonin injection 8 mg / mL: 0.008 g of melatonin was dissolved in 0.05 mL of dimethyl sulfoxide, and the resulting solution (mass concentration: 0.16%) was mixed with 0.95 mL of normal saline to obtain melatonin Injection;

[0052] (3) From the 28th day of subcutaneous immunization, 0.2 mL melatonin injection was intraperitoneally injected into the EAP mice at 8-9 o'clock every morning (once a day, the total injection volume was 80 mg / kg / d) until the 28th day. The mice were sacrificed on day 42; the degree of inflammation was evaluated according to histopathology, EAP mouse plantar pain measurement, and peripheral blood ELISA detection, and then NLRP3, ASC, caspase-1, IL -Expression of 1β and Sirt1.

Embodiment 2

[0054] (1) The mouse model of autoimmune prostatitis was established by subcutaneously injecting the mixture of prostate antigen and complete Freund's adjuvant (volume ratio 1:1) into non-obese diabetic mice (NOD) on day 0 and day 28 ( EAP);

[0055] (2) Use the melatonin injection 8 mg / mL prepared in Example 1, and simultaneously prepare the Sirt1 inhibitor-EX527 injection 0.5 mg / mL: 0.0005 g EX527 is dissolved in 0.05 mL dimethyl sulfoxide, and the resulting solution ( The mass concentration is 0.1%) mixed with 0.95mL physiological saline to obtain Sirt1 inhibitor-EX527 injection;

[0056] (3) From the 28th day of subcutaneous immunization, intraperitoneally inject melatonin injection (once a day, the volume of each injection is 0.2 mL, and the total daily injection volume is 80 mg / kg) to EAP mice at 8 to 9 o'clock every morning. / d), until the mice were killed on the 42nd day;

[0057] (4) From the day before melatonin injection, intraperitoneally inject Sirt1 inhibitor-E...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of melatonin to preparation of a medicine for treating autoimmune prostatitis and the medicine for treating the autoimmune prostatitis, and belongs to the technical field of medicine application. According to the invention, by enhancing a Sirt1 pathway and inhibiting the NLRP3 inflammasome, the inflammatory change and pain response of prostate tissue and the content of inflammatory cytokines in peripheral blood are reduced. According to the invention, an autoimmune prostatitis mouse model is taken as a test object, and research finds that the melatonin obviously reduces the inflammatory change and pain response of the prostate tissue and the content of inflammatory cytokines in the peripheral blood by enhancing the Sirt1 pathway and inhibiting the NLRP3 inflammasome, namely that the melatonin inhibits the expression of the NLRP3 inflammasome through Sirt1 dependency to reduce prostatitis, and the melatonin is feasible and effective for treating prostatitis.

Description

technical field [0001] The invention relates to the technical field of medicine application, in particular to the application of melatonin in the preparation of medicine for treating autoimmune prostatitis and the medicine for treating autoimmune prostatitis. Background technique [0002] Chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS), known as class III prostatitis, is a common urological disease among men under the age of 50, accounting for 90% of all prostatitis cases, and its incidence is about 8.4% . The most common symptoms of CP / CPPS include chronic pelvic pain mainly in the pelvis, perineum, scrotum and testicles. Since the etiology of CP / CPPS is still unclear, the current treatment methods for CP / CPPS are not satisfactory to patients and doctors. Therefore, in-depth research on the etiology of CP / CPPS is particularly important for exploring effective treatments for CP / CPPS. [0003] NLRP3, caspase-1 and apoptosis-associated speck-like protein (ASC) co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4045A61K9/08A61K47/20A61P29/00A61P13/08
CPCA61K31/4045A61K9/0019A61K9/08A61K47/20A61P29/00A61P13/08
Inventor 陈晶梁朝朝张力金宗兰张蒙张礼刚
Owner THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products